Blood Pressure Control with Angiotensin Receptor Blockers

Guideline Recommendations for ARB Selection

• The European Society of Cardiology/Hypertension guidelines emphasize that differences in cardiovascular outcomes between ARBs are generally small when BP reductions are equivalent, suggesting the benefit largely depends on BP lowering per se rather than specific agent selection 1, 2
• The European Society of Cardiology/Hypertension guidelines suggest that losartan reduced major cardiovascular events by 13% compared to atenolol with equivalent BP control, with a 25% reduction in stroke 3, 4
• The European Society of Cardiology/Hypertension guidelines demonstrate that valsartan addition reduced stroke by 40% in high-risk Japanese patients, though this was an add-on study rather than direct comparison 1, 2
• The European Society of Cardiology/Hypertension guidelines show that the VALUE trial comparing valsartan to amlodipine showed slightly lower BP with amlodipine, and no significant difference in primary cardiac outcomes, though valsartan trended toward better heart failure prevention 1, 5

Dosing and Clinical Decision-Making

• The European Society of Cardiology/Hypertension guidelines indicate that higher doses of ARBs provide greater benefit, as demonstrated by the HEAAL trial which showed losartan 150 mg daily was superior to 50 mg daily, with a 10% relative risk reduction in death or HF hospitalization (P=0.027) 6, 7
• The American Heart Association suggests that for heart failure, valsartan has more robust outcome data 7, 8